Mix Online [13 December 2018]
“武田薬品とエーザイ 化合物ライブラリー提供で新規抗菌薬開発目指す AMR対策でGARDPと” – “Takeda Pharmaceutical and Eisai aim to develop new antimicrobial drugs by providing compound libraries to GARDP”
Yakup [12 December 2018]
“한국파스퇴르연구소, 신규 항생제 개발 국제 공동연구 참여” – “Korea Pasteur Institute participates in an international joint research on the development of new antibiotics”
Pharmaceutical Technology [12 December 2018]
“GARDP, Eisai and Takeda join forces to identify new antibiotics”
Pharmaphorum [12 December 2018]
“Eisai, Takeda and GARDP hunt for new antibiotics”
[Tokyo/Geneva – 12 December 2018]
First multi-actor partnership tests chemical compounds for antibacterial activity
GARDP, Eisai, and Takeda have signed an agreement for GARDP to access and screen components of Eisai and Takeda’s chemical libraries. Both libraries will be tested by the Institut Pasteur Korea in the hope of discovering novel compounds with antibacterial activity. This multi-partner agreement supports GARDP’s efforts to tackle serious bacterial infections by developing antibiotics while endeavouring to ensure their sustainable access.
배포일: 2018년 12월 12일
GARDP-에자이-다케다제약, 다자간 글로벌 파트너십 맺고 화합물 항균력 테스트 착수
한국파스퇴르연구소(소장: 류왕식)는 글로벌 항생제 연구개발 비영리 국제단체 (Global Antibiotic Research & Development Partnership, 이하 GARDP)와 일본계 글로벌 제약사들이 진행하는 새로운 항생제 개발 연구에 참여한다. GARDP는 최근 일본 글로벌 제약사 에자이(Eisai Co., Ltd., 이하 에자이), 다케다제약(Takeda Pharmaceutical Company Limited, 이하 다케다제약)과 항생제 개발 연구를 위한 다자간 파트너십 협약을 맺고 두 제약사가 제공하는 화합물 라이브러리를 활용한 항생제 개발 연구를 착수하였으며, 한국파스퇴르연구소 연구팀은 자체 구축된 초고속 약효검색 시스템을 이용하여 화합물 라이브러리로부터 항균물질 도출 및 검증 연구를 수행한다.
Global Antibiotic Research and Development Partnership (グローバル抗菌薬研究開発パートナーシップ、本部：スイス・ジュネーブ、以下「GARDP」)、エーザイ株式会社 (本社：東京都文京区、以下「エーザイ」) および武田薬品工業株式会社 (本社：大阪市中央区、以下「武田薬品」) は、抗菌活性を有する新たな化合物を発見することを目指し、エーザイおよび武田薬品の化合物ライブラリーを用いたGARDPによるスクリーニング実施に関する契約を締結しました。今後、エーザイおよび武田薬品から提供された化合物の抗菌活性試験はInstitut Pasteur Korea (所在地：キョンギド・ソンナム市、以下「韓国パスツール研究所」) にて実施されます。複数のパートナーによる本契約は、新規抗菌薬の開発と持続可能なアクセスの担保により、深刻な細菌感染症に立ち向かうGARDPの取り組みを推し進めるものです。
Global Healthcare [4 December 2018]
“Novartis Social Business: Blending profit with purpose”
Center for Infectious Disease Research and Policy [8 November 2018]
“New gonorrhea antibiotic shows efficacy in small trial”
13 November 2018
Time: 17:00-18:30 CET
In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programmes.
Pharmacy Business [3 October 2018]
“Novartis and GARDP join forces to help children get quicker access to antibiotics globally”
Infectious Diseases Hub [27 September 2018]
“Novartis and GARDP partner to accelerate the availability of antibiotics for children”
Pharmafile [27 September 2018]
“Novartis joins forces with GARDP for better, accessible infectious disease treatments in the developing world”
[Geneva – 22 May 2018]
PLOS, in collaboration with GARDP, is delighted to announce the launch of the Antimicrobial Resistance (AMR) Channel during the World Health Assembly, Geneva. This new channel offers the AMR research community access to the latest research, as well as commentaries, blogs, news, and discussions that span science, research and development, policy, and public health in the fight against AMR.
[26 April 2018]
Funding will support studies on new treatments for neonatal sepsis and drug-resistant STIs in South Africa
GARDP is pleased to announce the strengthening of its collaborative efforts with the SAMRC. This funding will contribute to the global development and delivery of affordable new or improved antibiotic treatments for drug-resistant bacterial infections where there are currently no adequate treatments, beginning with neonatal sepsis and sexually transmitted infections (STIs).
Korea Biomedical Review [24 April 2018]
“Pharma group asks members to join in developing new antibiotics”
The Telegraph [15 March 2018]
“New thinking is required to create desperately needed new antibiotics. We must act now”
22 May 2018
Event organized by GARDP and PLOS for the launch of the PLOS AMR Channel
Manica Balasegaram, Director GARDP – panel discussion and closing remarks